Logo image of MLSS

MILESTONE SCIENTIFIC INC (MLSS) Stock Fundamental Analysis

NYSEARCA:MLSS - NYSE Arca - US59935P2092 - Common Stock - Currency: USD

0.54  +0.01 (+2.08%)

After market: 0.551 +0.01 (+2.04%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MLSS. MLSS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. MLSS may be in some trouble as it scores bad on both profitability and health. MLSS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MLSS had negative earnings in the past year.
MLSS had a negative operating cash flow in the past year.
MLSS had negative earnings in each of the past 5 years.
MLSS had a negative operating cash flow in each of the past 5 years.
MLSS Yearly Net Income VS EBIT VS OCF VS FCFMLSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

MLSS's Return On Assets of -57.96% is on the low side compared to the rest of the industry. MLSS is outperformed by 69.52% of its industry peers.
MLSS's Return On Equity of -118.05% is on the low side compared to the rest of the industry. MLSS is outperformed by 66.31% of its industry peers.
Industry RankSector Rank
ROA -57.96%
ROE -118.05%
ROIC N/A
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
MLSS Yearly ROA, ROE, ROICMLSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

MLSS has a Gross Margin of 74.37%. This is amongst the best in the industry. MLSS outperforms 86.63% of its industry peers.
In the last couple of years the Gross Margin of MLSS has grown nicely.
MLSS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
MLSS Yearly Profit, Operating, Gross MarginsMLSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
MLSS has more shares outstanding than it did 1 year ago.
MLSS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MLSS is higher compared to a year ago.
MLSS Yearly Shares OutstandingMLSS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MLSS Yearly Total Debt VS Total AssetsMLSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

MLSS has an Altman-Z score of -15.68. This is a bad value and indicates that MLSS is not financially healthy and even has some risk of bankruptcy.
MLSS has a Altman-Z score of -15.68. This is amonst the worse of the industry: MLSS underperforms 86.10% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that MLSS is not too dependend on debt financing.
MLSS has a better Debt to Equity ratio (0.01) than 68.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -15.68
ROIC/WACCN/A
WACC8.86%
MLSS Yearly LT Debt VS Equity VS FCFMLSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

MLSS has a Current Ratio of 1.94. This is a normal value and indicates that MLSS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.94, MLSS is doing worse than 66.31% of the companies in the same industry.
MLSS has a Quick Ratio of 1.94. This is a bad value and indicates that MLSS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.79, MLSS is doing worse than 86.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 0.79
MLSS Yearly Current Assets VS Current LiabilitesMLSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.22% over the past year.
The Revenue has decreased by -9.14% in the past year.
MLSS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.61% yearly.
EPS 1Y (TTM)30.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-9.14%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-0.69%

3.2 Future

Based on estimates for the next years, MLSS will show a very strong growth in Earnings Per Share. The EPS will grow by 24.37% on average per year.
Based on estimates for the next years, MLSS will show a quite strong growth in Revenue. The Revenue will grow by 17.56% on average per year.
EPS Next Y49%
EPS Next 2Y24.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.45%
Revenue Next 2Y17.56%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MLSS Yearly Revenue VS EstimatesMLSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
MLSS Yearly EPS VS EstimatesMLSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MLSS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLSS Price Earnings VS Forward Price EarningsMLSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLSS Per share dataMLSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1

4.3 Compensation for Growth

MLSS's earnings are expected to grow with 24.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MLSS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE SCIENTIFIC INC

NYSEARCA:MLSS (8/6/2025, 8:04:00 PM)

After market: 0.551 +0.01 (+2.04%)

0.54

+0.01 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-19 2025-08-19
Inst Owners5.33%
Inst Owner Change-0.1%
Ins Owners6.15%
Ins Owner Change-0.9%
Market Cap42.38M
Analysts82.86
Price Target2.17 (301.85%)
Short Float %0.13%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-112.42%
Min EPS beat(2)-194.12%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-104.25%
Min EPS beat(4)-194.12%
Max EPS beat(4)-30.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.86%
Min Revenue beat(2)-25.64%
Max Revenue beat(2)-10.09%
Revenue beat(4)0
Avg Revenue beat(4)-17.33%
Min Revenue beat(4)-27.95%
Max Revenue beat(4)-5.64%
Revenue beat(8)1
Avg Revenue beat(8)-15.15%
Revenue beat(12)3
Avg Revenue beat(12)-12.82%
Revenue beat(16)5
Avg Revenue beat(16)-9.72%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)-2.99%
Revenue NY rev (3m)-2.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.92
P/FCF N/A
P/OCF N/A
P/B 9.5
P/tB 9.78
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.11
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.96%
ROE -118.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.37%
FCFM N/A
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
F-Score4
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.77%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 0.79
Altman-Z -15.68
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)9.14%
Cap/Depr(5y)15.64%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y49%
EPS Next 2Y24.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.14%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-0.69%
Revenue Next Year14.45%
Revenue Next 2Y17.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.44%
OCF growth 3YN/A
OCF growth 5YN/A